Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Must have received: cytotoxic chemotherapy — PDAC, NSCLC (no actionable alteration), CRC

disease progression following, or intolerance to cytotoxic therapy/chemotherapy

Must have received: chemotherapy and immunotherapy — NSCLC (no actionable alteration)

disease progression following, or intolerance to chemotherapy and immunotherapy

Must have received: chemotherapy and targeted therapy — NSCLC with actionable alteration

disease progression following, or intolerance to chemotherapy and targeted therapy

Must have received: hormone therapy and CDK4/6 inhibitor and at least one additional line — HR+/HER2- breast cancer

disease progression following, or intolerance to, hormone therapy and CDK inhibitor, and at least one additional line of therapy

Must have received: at least two lines of therapy — TNBC

disease progression following, or intolerance to, at least two lines of therapy

Must have received: at least one line of systemic therapy — soft tissue sarcoma

disease progression following, or intolerance to, at least one line of systemic therapy

Must have received: immune checkpoint inhibitor — CRC with MSI-H or dMMR

disease progression following, or intolerance to, immune checkpoint inhibitor therapy

Cannot have received: radioligand therapy

Any prior radioligand therapy

Cannot have received: radiation therapy

Exception: within 4 weeks prior to the first dose

Radiation therapy within 4 weeks prior to the first dose of [177Lu]Lu-DFC413